Education
About Us
Working with TipRanks
Follow Us
Hepion Pharmaceuticals (HEPA)
OTHER OTC:HEPA
HEPA Stock Chart & Stats
$0.06
-$0.04(-7.39%)
At close: 4:00 PM EST
$0.06
-$0.04(-7.39%)
Day’s Range― - ―
52-Week Range$0.03 - $36.70
Previous Close$0.56
Volume20.84K
Average Volume (3M)24.29K
Market Cap
$801.80K
Enterprise ValueN/A
Total Cash (Recent Filing)$2.32M
Total Debt (Recent Filing)$214.31K
Price to Earnings (P/E)―
Beta0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-109.30
Shares Outstanding11,620,317
10 Day Avg. Volume18,147
30 Day Avg. Volume24,289
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.55
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-312.5
Revenue Forecast (FY)N/A
Hepion Pharmaceuticals News
HEPA FAQ
What was Hepion Pharmaceuticals’s price range in the past 12 months?
Hepion Pharmaceuticals lowest stock price was $0.03 and its highest was $36.70 in the past 12 months.
What is Hepion Pharmaceuticals’s market cap?
Hepion Pharmaceuticals’s market cap is $801.80K.
When is Hepion Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hepion Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Hepion Pharmaceuticals overvalued?
According to Wall Street analysts Hepion Pharmaceuticals’s price is currently Overvalued.
Does Hepion Pharmaceuticals pay dividends?
Hepion Pharmaceuticals does not currently pay dividends.
What is Hepion Pharmaceuticals’s EPS estimate?
Hepion Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hepion Pharmaceuticals have?
Hepion Pharmaceuticals has 11,620,317 shares outstanding.
What happened to Hepion Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hepion Pharmaceuticals?
Currently, no hedge funds are holding shares in HEPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Conduit Pharmaceuticals
―
Ownership Overview
―
Insiders
8.11% Other Institutional Investors
91.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---